Periodic Reporting for period 1 - C-TCS (A Disruptive Treatment Control Software for Particle Therapy Centers)
Período documentado: 2018-08-01 hasta 2018-11-30
The number of cancer cases grows by 2.4% per year. Particle Therapy (PT) is the most efficient and fastest growing treatment method but it is expensive and thus scarcely available: currently, only 12% of the population in need has access to it. In addition, PT equipment manufacturers need to develop their own custom Treatment Control System (TCS), which is unpractical and expensive.
C-TCS is creating a new market niche by creating the first (1) standalone off-the-shelf modular TCS (2) universal -compatible with all vendors’ devices-, (3) scalable and easily configurable, (4) user friendly, (5) highly accurate and (6) available without lead times. In addition, (7) C-TCS costs 3x-less than custom development and therefore reduces the PT centre initial investment. Furthermore, it will increase in 30% patient throughput. This will impact PT centre construction rate and reduce of time-to-treatment by 1-2 years.
We are already collaborating with several device vendors that wish to outsource their TCS development through COSYLAB.
After being awarded SME Instrument Phase 1, the main challenge is to optimize and integrate the modules, test the integration and validate it in a real PT centre. Meanwhile, we will prepare our European market uptake.
C-TCS is creating a new market niche by creating the first (1) standalone off-the-shelf modular TCS (2) universal -compatible with all vendors’ devices-, (3) scalable and easily configurable, (4) user friendly, (5) highly accurate and (6) available without lead times. In addition, (7) C-TCS costs 3x-less than custom development and therefore reduces the PT centre initial investment. Furthermore, it will increase in 30% patient throughput. This will impact PT centre construction rate and reduce of time-to-treatment by 1-2 years.
We are already collaborating with several device vendors that wish to outsource their TCS development through COSYLAB.
After being awarded SME Instrument Phase 1, the main challenge is to optimize and integrate the modules, test the integration and validate it in a real PT centre. Meanwhile, we will prepare our European market uptake.
At this stage, we have developed the software and demonstrated it in a relevant environment (beta-testers: prospective clients). During the Feasibility Study we have developed several thorough assessments: (1) The technical implementation and work plan for Phase 2 plus identification of implicit risks and establishment of mitigation plans. (2) A work plan including schedules and cost baselines. (3) A detailed study of our stakeholders, partners and prospective clients and a thorough market analysis, both global and European. (4) An exhaustive patent search as well as regulations and certifications and market uptake plan for commercialization, analysing also the implicit risks and mitigation measures. (5) Finally, we developed the project budget, a five-year financial projection and a detailed business plan.
By the end of the project we will be ready to sell C-TCS based on our European market uptake plan. We will have approached prospective clients for testing and established further commercial agreements. By 2025, 5 years after commercialization, we expect to reach a cumulated revenue of €53.35 with a profit of €47M through our one-time license and our yearly maintenance incomes. We will create 20 new European jobs.